NCT06185400View on ClinicalTrials.gov

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

December 1, 2026

Conditions
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene DuplicationDisitamab Vedotin
Interventions
DRUG

Disitamab Vedotin

RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC

DRUG

third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)

RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression

DRUG

pyrotinib

RC48+pyrotinib after EGFR-TKIs progression

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06185400 - RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | Biotech Hunter | Biotech Hunter